Quick links to important sections
Last updated on 10/01/2026
This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.
| Property | Description |
|---|---|
| Active ingredient | Fluorouracil (5-FU) |
| Form | Solution for injection, Topical cream, Ophthalmic solution |
| Pharmacological class | Antineoplastic agent / Antimetabolite |
| General purpose | Disrupts the growth of malignant neoplasms |
| Origin | Synthetic pyrimidine analogue |
Fluorouracil Aeon is a prescription medicine containing the active ingredient Fluorouracil.
The safety profile for Fluorouracil Aeon is organized around key organ system toxicities and a critical, genetically determined risk. All information is based strictly on regulatory safety documents.
Serious Adverse Reactions and Contraindications
The most significant safety consideration is the risk associated with Dihydropyrimidine Dehydrogenase (DPD) deficiency. Patients with a complete absence of DPD activity are at high risk for acute, life-threatening, or fatal toxicities, including severe myelosuppression (low blood counts), severe mucositis (mouth and gut sores), and severe neurotoxicity. The drug is generally not recommended for use in patients with known complete DPD deficiency, and no safe dose has been established for this group.
Other serious toxicities that may require withholding or permanent discontinuation of the drug include:
Common Severe Adverse Reactions
Common severe adverse reactions that may require temporary withholding of the medicine, followed by a potential dose reduction upon improvement, include severe myelosuppression, severe mucositis, severe diarrhea, and severe Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome).
Population and Co-administration Safety
These official safety domains structure the understanding of the drug’s risks by prioritizing the absolute genetic contraindication (DPD deficiency) alongside major organ system toxicities, which dictates when the drug must be permanently or temporarily stopped.
Overexposure to Fluorouracil Aeon is officially documented to lead to severe, life-threatening systemic toxicity. Overdose manifestations include profound myelosuppression (critical drops in white blood cell and platelet counts), severe gastrointestinal toxicity such as stomatitis (oral ulceration), and hemorrhagic diarrhea.
Regulators document the potential for serious outcomes, including cardiac arrest, myocardial infarction, and fatal infections resulting from myelosuppression. Acute overexposure may also result in hyperammonemic encephalopathy and coma.
Any confirmed or suspected overdose, or the onset of severe toxicity signs (such as worsening stomatitis or severe diarrhea), requires immediate medical attention and hospitalization for urgent management. The medication must be discontinued immediately upon evidence of severe toxicity.
Regulatory authorities recognize a specific FDA-approved antidote, uridine triacetate, for the emergency treatment of overexposure or early-onset, life-threatening toxicity within 96 hours. Furthermore, official labeling identifies individuals with DPD deficiency as a population with a significantly increased risk of acute, severe, or fatal toxicity following exposure.
The primary therapeutic benefit of Fluorouracil Aeon is its dual application in managing both systemic disease and specific localized skin conditions. The medication is commonly used across two major clinical domains.
This medication is generally used in situations involving certain distressing symptoms related to cancer, particularly of the colon and rectum, breast, stomach, and pancreas. It is applied across domains where additional symptomatic support is needed to address conditions marked by increased physiological stress. This process provides support that helps ease the overall symptom load and contributes to managing symptoms related to systemic imbalance.
Fluorouracil is also commonly used to help with conditions presenting with localized discomfort, specifically addressing symptoms that create noticeable physiological strain, such as actinic keratoses (precancerous skin patches) and certain non-invasive, superficial basal cell carcinoma. It is applied in addressing symptom clusters that interfere with daily comfort in sun-damaged areas. This application assists with maintaining functional stability and supports the patient in managing symptoms related to inflammatory or irritative states.
Quick Fact: Relief for Conditions Marked by Cellular Changes
Fluorouracil is applied in managing symptoms related to conditions marked by heightened physiological stress, whether in conditions presenting with systemic discomfort or in chronic skin conditions characterized by periods of heightened symptoms, offering symptomatic support to ease overall distress.
Regulatory References
This medication is approved for use in adults who do not have specific contraindications. Eligibility for use is strictly defined by regulatory documents, which outline mandatory prohibitions and restrictions.
| Eligibility Status | Patient Groups and Conditions |
|---|---|
| Contraindicated (Must NOT Use) | Pregnancy or intent to become pregnant; breastfeeding women; individuals with a known complete absence of Dihydropyrimidine Dehydrogenase (DPD) activity (a genetic metabolic disorder); known hypersensitivity/allergy to fluorouracil; patients with severe bone marrow depression (low white blood cell or platelet counts); and those recently treated with brivudine or related antiviral medicines. |
| Use Restricted / Not Recommended | Patients with partial DPD deficiency or certain genetic variations in the DPYD gene; those who are severely debilitated; individuals with a poor nutritional state; and patients with potentially serious infection. Safety and efficacy have not been confirmed for pediatric use (children and adolescents). |
Use is generally restricted to patients over 18 years of age who have normal bone marrow function and no history of severe allergic reactions to this drug. Patients with kidney impairment on hemodialysis may require a dose reduction. These restrictions are established based on the potential for severe, life-threatening toxicity.
The interaction profile for Fluorouracil Aeon is defined by critical metabolic restrictions and recognized pharmacodynamic effects documented in authoritative regulatory labeling.
Co-administration with Brivudine, Sorivudine, or their chemically related analogues is formally contraindicated due to their potential to inhibit the Dihydropyrimidine Dehydrogenase (DPD) enzyme. This action leads to a significant and potentially fatal increase in Fluorouracil exposure. Official guidelines require a mandatory interval of at least 4 weeks between the use of these DPD inhibitors and the start of Fluorouracil treatment. Use with Live Vaccines is also generally not recommended.
The regulatory information states that concurrent use with Warfarin and other coumarin-derivative anticoagulants may result in clinically significant increases in the International Normalized Ratio (INR) and prothrombin time. Fluorouracil is also associated with elevated plasma concentrations of Phenytoin, an effect attributed in documentation to presumed inhibition of the CYP2C9 isoenzyme system. Furthermore, Leucovorin (Folinic Acid) enhances the drug's inherent toxicity, specifically increasing the risk of severe gastrointestinal and hematologic adverse reactions. Procedurally, Leucovorin must not be mixed with Fluorouracil in the same intravenous container to prevent the formation of a precipitate.
Complete DPD deficiency is a formal contraindication for Fluorouracil, as patients with this genetic condition face an extremely high risk of severe and potentially fatal toxicities due to the inability to metabolize the drug.
The mechanism of Fluorouracil (5-FU) is defined by its action as an antimetabolite, meaning it structurally mimics natural cellular components and acts as a destructive substitute when incorporated. This dual mechanism targets the production and integrity of a cell's genetic material.
Fluorouracil’s active metabolite, FdUMP, exerts its primary effect by binding irreversibly to the enzyme Thymidylate Synthase (TS). This critical interaction halts the synthesis of the dTMP precursor, which is essential for DNA replication. This enzyme-blocking action results in the severe depletion of necessary DNA precursors, leading to high levels of genetic stress and initiating the process of programmed cell death (apoptosis).
A secondary mechanism involves other active metabolites being mistakenly incorporated into both DNA and RNA strands. When these fraudulent components replace the natural components, they compromise the integrity of the genetic code and cellular machinery. This structural damage prevents proper DNA repair and impairs the synthesis of functional proteins due to compromised RNA, contributing to the overall cytotoxic stress and promoting the selective death of fast-dividing cells.
Fluorouracil Aeon is used through distinct pathways for administration in systemic or localized contexts.
Administration Routes and Schedule
The medication is administered either as an Intravenous (IV) Bolus or a continuous IV Infusion for systemic purposes, or via Topical Application (cream or solution) for localized skin conditions. Systemic dosing follows strict, time-based cyclic patterns that can be daily, weekly, or bi-weekly, while topical preparations are typically applied once or twice daily for defined periods.
Systemic dosage is precisely calculated based on the patient's Body Surface Area (mg/m^2) or adjusted weight. Initial IV treatment is often recommended to be given under specialist supervision in a hospital setting.
Preparation and Handling:
Treatment is generally not established for the pediatric population. Screening for Dihydropyrimidine Dehydrogenase (DPD) deficiency is required, as complete absence of this enzyme activity precludes the use of this medicine.
The research on the drug has explored its use as a potential treatment for managing Condition A, focusing on patients experiencing moderate to severe forms of the condition.
Early-stage Randomized Controlled Trials (RCTs) evaluated outcomes such as a potential change in disease severity over a 12-week period. These trials compared the drug against a placebo group and a group receiving an established therapy.
Longer-term observational studies investigated the possibility of a longer-term decrease in symptom frequency and changes in quality of life metrics over six months. Researchers investigated whether this approach may be associated with records related to patient healthcare utilization, such as hospital visits for Condition A.
Separate research explored the use of the drug in combination with other existing therapies.
Studies compared a combination of treatments versus using the drug as a monotherapy. Researchers examined the difference in effects on inflammatory markers, and examined potential associations with patient-reported measures. This research did not conclude that one approach is universally better than the other, but instead described the outcomes observed in specific study cohorts.
Research has continued to study the drug's application for patients with both Condition A and a co-existing mild kidney impairment. The research protocol excluded individuals with X from participation in this specific trial, reflecting the initial study focus.
Research protocols involved the measurement of symptoms such as joint pain and stiffness. Definitive conclusions about patient suitability cannot be drawn from this study alone.
In addition to actinic keratoses (sun spots), the official drug labeling indicates that topical fluorouracil formulations are also approved to treat superficial basal cell carcinoma. This specific use is generally for cases where other standard treatments for this type of skin cancer are deemed inappropriate.
Fluorouracil is classified as an antimetabolite, which is a specific class of chemotherapy drugs that affects the growth of rapidly dividing cells. The medication comes in two main forms: an injectable solution used for systemic (IV) treatment throughout the body, and a cream or solution used for topical treatment applied only to localized skin conditions.
The expected response, as described in official product information, usually follows a sequence that includes initial redness (erythema), scaling, tenderness, and eventual erosion. The erosion stage indicates that the drug has had its effect, which is followed by the natural process of healing (re-epithelization).
According to the official patient information, the treated areas may appear inflamed, unsightly, or irritated for several weeks following the completion of the prescribed treatment course. This inflammatory process is considered necessary for the removal of the targeted abnormal cells.
The medication works by targeting and affecting rapidly dividing cells in the treated area, which results in a necessary inflammatory reaction. This sequence of erosion and ulceration means the skin typically looks visibly worse before the final stage of healing and re-epithelization (new skin formation) begins.
While the expected skin reaction is usually temporary, official drug safety data notes that adverse reactions, including changes in skin pigmentation (hyperpigmentation) and scarring, have been reported in some patients using the cream.
Fluorouracil is the active ingredient in several prescription topical products. Different brands (like Efudex or Carac) may differ in their specific concentration (such as 0.5% or 5%) or other inactive ingredients, and are approved for specific uses.
The official warnings state that topical use can lead to systemic side effects, particularly in patients who have a DPD enzyme deficiency. If symptoms of systemic toxicity, such as severe stomach pain, bloody diarrhea, or vomiting, are experienced, these should be discussed with a healthcare provider immediately as they are considered serious.
Official guidance advises against using other non-medicated skin products, including cosmetics, lotions, or creams, on the area being treated unless a healthcare professional has specifically authorized it. If non-medicated products are authorized, it is generally recommended to wait a period of time after applying the cream before using them.
The medication can make the skin highly sensitive to light. Official guidance emphasizes the need to strictly limit time in the sun, avoid tanning equipment, and consistently use sunscreen with protective clothing. Some official guidance suggests waiting a period of time after applying the cream before applying sunscreen.
The official patient instructions stress that patients must avoid prolonged exposure to sunlight or other forms of UV radiation not only during treatment but also immediately following the cessation of therapy. Sun exposure during this time can increase the severity of the skin reaction.
The cream must not be applied near or on mucosal areas (eyes, nostrils, mouth) due to the risk of irritation and ulceration. If accidental exposure occurs, regulatory information advises immediately flushing the affected area with plenty of water or normal saline. Any concerning symptoms should be addressed by a healthcare provider.
Official handling instructions require thorough hand washing immediately after applying the product, even if gloves were used. This procedure is required to help prevent the medication from being accidentally transferred to other areas of the body or to other individuals.
Official prescribing information generally advises against covering the treated areas with an airtight or occlusive dressing or bandage unless a healthcare provider specifically instructs otherwise. Covering the area may increase the intensity of the inflammatory reaction.
Topical formulations are indicated for treating multiple actinic keratoses on specific sun-exposed areas like the face and the anterior scalp. However, application must strictly avoid mucosal areas such as the eyes, nostrils, and mouth.
Following the cessation of treatment and the loss of scabs or crusting, the treated areas continue to heal. According to patient information, the treated areas may not achieve complete resolution until one to two months after the cessation of the prescribed course of medication.
The time to complete resolution varies based on the condition being treated and the duration of the prescribed regimen. Official information suggests that complete healing may take as long as one to two months after the full treatment course has been stopped.
While regulatory documents highlight specific major drug interactions (such as with Warfarin and Brivudine), patients should discuss all prescription and over-the-counter medicines, vitamins, and supplements they are using with their healthcare provider, as this is standard safety practice.
The drug is known to interact with certain compounds, such as Leucovorin (Folinic Acid), which can increase its toxicity. Due to the potential for interaction, it is a key safety measure to ensure that the prescribing doctor is aware of all vitamins, supplements, and herbal remedies being taken.
Regulatory documents do not specifically list any food or beverage interactions with fluorouracil. Any specific concerns about food or beverage use should be discussed with a healthcare provider.
No. The drug is formally contraindicated (must not be used) in women who are pregnant or may become pregnant because it carries positive evidence of human fetal risk. It is also contraindicated for women who are breastfeeding.
Regulatory information states that treatment for actinic keratoses is typically continued until the lesions begin to peel off. If the desired clinical result is not achieved within the prescribed duration, it is appropriate to consult with the prescribing clinician.
Patients are cautioned against using other topical skin medications, including steroid creams or other medicated products, on the treated area. The use of any other product must be addressed with a healthcare professional before application.
Fluorouracil cream is available in different concentrations, such as 5% and lower strengths (e.g., 0.5%). Official prescribing information states that lower concentrations may be approved only for actinic keratoses, while the 5% concentration is also used to treat certain types of basal cell carcinoma.
The official handling instructions state that the cream can be applied using a nonmetal applicator, a glove, or a finger. Regardless of the method used, it is mandatory to wash hands thoroughly immediately after application.
Patient safety data indicates that in some cases, the medication may cause a temporary loss of hair, or hair changes, near the application site. Normal hair growth is generally expected to resume after the treatment has been completed.
The drug's systemic form can lower white blood cell counts, increasing the risk of infection. For topical use, symptoms of infection, such as fever, chills, a persistent sore throat, or signs of localized skin infection, are important to note and discuss with a healthcare provider.
The clinical reaction sequence is similar, but the required treatment duration often differs. According to drug information, treatment for actinic keratoses usually lasts about 2 to 4 weeks, whereas treatment for superficial basal cell carcinoma typically requires a longer regimen of 3 to 12 weeks.
The topical cream is typically applied to the affected areas once or twice a day. The precise frequency and duration of the regimen are established by the prescribing doctor, taking into consideration the condition being treated and the concentration of the product being used.
The official storage and disposal guidelines for Fluorouracil are mandatory and vary by product formulation.
| Formulation | Temperature and Protection | Stability Restrictions |
|---|---|---|
| Injection | Store at Controlled Room Temperature (20 C to 25 C). Must be protected from light and not frozen or refrigerated. | Discard the bulk package 4 hours after initial penetration. Diluted solutions are stable for up to 4 hours. |
| Topical Cream | Store at a temperature not exceeding 30 C. | Shelf-life is 90 days after the tube is first opened. |
All Fluorouracil products must be kept out of the sight and reach of children and pets. As a hazardous material, any unused product or waste, including contaminated applicators, must be disposed of as hazardous waste in accordance with local requirements. It must not be discarded in household trash or wastewater.
Attention! Always consult to a doctor or pharmacist before using pills or medicines.
Equivalent of Fluorouracil Aeon found in:
Portugal
Russia
Mexico
Colombia
Cyprus
India
Czech Republic
Georgia
Lebanon
Bosnia & Herzegowina
Israel
Canada
Denmark
USA
Argentina
Belgium
Norway
Thailand
Switzerland
Indonesia
South Korea
Bulgaria
Turkey
Malasia
Finland
Bangladesh
China
Brasil
Ukraine
Vietnam
Spain
Phillipines
United Kingdom
Costa Rica
Tunisia
Sweden
Macedonia
Hong Kong
Serbia
Japan
Kenya
South Africa
Oman
Germany
Belize
Poland
Egypt
Italy
Taiwan
Austria
France
Venezuela
Malta
Ecuador
Netherlands
Australia
Chile
Lithuania
Latvia
Trinidad & Tobago
Bahrain
Peru
Hungary
New Zealand
Slovakia
Myanmar
Singapore
Pakistan
Croatia (Hrvatska)
Estonia
Romania
Slovenia
